- Remove All
- Your shopping cart is currently empty
- A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related diseases;
- Bioactivity and safety confirmed by pre-clinical research and clinical trials, and some of them are approved by FDA;
- Targets include c-Kit, c-Met, EGFR, FGFR, SRC, JAK, SYK, Btk, Bcr-Abl, etc;
- Detailed compound information with structure, target, activity, IC50 value, and biological activity description;
- Structurally diverse, medicinally active, and cell permeable;
- NMR and HPLC validated to ensure high purity and quality;